Extended-Release Risperidone Approved by FDA for Schizophrenia - Drug Topics
Rykindo is a bi-weekly long-acting risperidone injection to treat patients with schizophrenia and bipolar 1 in adults. The FDA has approved Rykindo (risperidone) to treat adults with schizophrenia and as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. Developed by China-based company Luye Pharma Group, Rykindo is an extended-release injectable suspension administered via intramuscular injection once every two weeks. It was developed using Luye Pharma's microsphere technology platform. In the United States, there are about 24 million schizophrenia patients, and the estimated prevalence of schizophrenia and related psychotic disorders ranges between 0.25% and 0.64%. An estimated 4.4% of U.S. adults experience bipolar disorder at some point in their lives. Rykindo has a black-box warning about use in elderly patients. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of d...